VERV News and Press, Verve Therapeutics Inc.

NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NA...

NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities are encouraged to obtain additional informat...

2024-04-06 09:50:00 ET Verve Therapeutics (NASDAQ: VERV) saw its shares crater by 36% on April 2 when it reported that a serious mishap had occurred in one of its clinical trials. Understandably, investors may now question whether the gene-editing biotech has a shot at recovering, o...

2024-04-05 14:32:16 ET More on Markets AllianceBernstein spotlights demand shifts in the EV industry We're seeing new money come into Bitcoin – TD Securities Treasury yields continue to climb, see what SA analysts have to say AllianceBernstein warns of...

2024-04-03 14:15:00 ET Summary Verve is targeting patients with genetically-driven high cholesterol levels, and they are making a single A-to-G change in the gene for the PCSK9 protein. Verve announced their results yesterday, and it's a glass-half-full story. They say that they'v...

2024-04-03 11:57:45 ET Summary Enrollment paused in the Verve Therapeutics' phase 1b heart-1 study, using VERVE-101 for the treatment of patients with heterozygous familial hypercholesterolemia after a Grade 3 adverse event. Despite VERVE-101 setback, the ability to move forward w...

2024-04-03 09:30:03 ET BMO Capital analyst issues OUTPERFORM recommendation for VERV on April 3, 2024 07:43AM ET. The previous analyst recommendation was Outperform. VERV was trading at $8.32 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

A look at the top 10 most actives in the United States Trio Petroleum Corp. (TPET) rose 43.8% to $0.1485 on volume of 202,621,744 shares Nikola Corporation (NKLA) fell 5.5% to $0.9736 on volume of 187,304,976 shares C3is Inc. (CISS) rose 13.3% to $0.0409 on volume of 136,767,990 shares ...

2024-04-02 14:30:01 ET RBC Capital analyst issues OUTPERFORM recommendation for VERV on April 2, 2024 12:59PM ET. The previous analyst recommendation was Outperform. VERV was trading at $8.215 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-04-02 13:01:35 ET Read the full article on Seeking Alpha For further details see: XTIA, TPET and GSIT among mid-day movers